<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Bayer AG (Germany) &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/bayer-ag-germany/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Fri, 13 Aug 2021 09:12:45 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>Bayer AG (Germany) &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>全球抗高血压药物市场研究报告预测至2023年：预测期内市场预计将以2.67％的复合年增长率增长</title>
		<link>https://www.yuanzhezixun.com/quanqiukanggaoxueyayaowushichangyanjiubaogaoyucezhi2023nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Tue, 23 Apr 2019 06:24:05 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[and United Therapeutics Corporation (U.S.)]]></category>
		<category><![CDATA[AstraZeneca (U.K.)]]></category>
		<category><![CDATA[Bayer AG (Germany)]]></category>
		<category><![CDATA[Boehringer Engelheim GmbH (Germany)]]></category>
		<category><![CDATA[Daiichi Sankyo Company]]></category>
		<category><![CDATA[Inc. (U.S.)]]></category>
		<category><![CDATA[Johnson & Johnson Services]]></category>
		<category><![CDATA[Merck KGaA (Germany)]]></category>
		<category><![CDATA[Novartis AG (Switzerland)]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Sanofi S.A. (France)]]></category>
		<category><![CDATA[Takeda Pharmaceutical Company (Japan)]]></category>
		<category><![CDATA[抗高血压]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=19501</guid>

					<description><![CDATA[知名临床医生开具抗高血压药物治疗高血压或高血压。高血压的普遍存在是全球抗高血压药物市场的重要推动力。一些政府和非营利协会的一些宣传活动可能会为市场效力。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>全球肛裂治疗市场研究报告预测至2023年</title>
		<link>https://www.yuanzhezixun.com/quanqiugangliezhiliaoshichangyanjiubaogaoyucezhi2023nian/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Tue, 23 Apr 2019 06:14:05 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Abbott Laboratories (U.S.)]]></category>
		<category><![CDATA[Allergan Inc. (U.S.)]]></category>
		<category><![CDATA[and Taro Pharmaceutical Industries Ltd. (Israel)]]></category>
		<category><![CDATA[AstraZeneca (U.K.)]]></category>
		<category><![CDATA[Bayer AG (Germany)]]></category>
		<category><![CDATA[Cigna (U.S.)]]></category>
		<category><![CDATA[Cook (U.S.)]]></category>
		<category><![CDATA[Eisai Co. Ltd. (Japan)]]></category>
		<category><![CDATA[GlaxoSmithKline Plc (U.K.)]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International Inc (Canada)]]></category>
		<category><![CDATA[肛裂治疗]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=19491</guid>

					<description><![CDATA[到2023年，市场预计将达到2,526.5百万美元的估值，预测期间（2018-2023）的复合年增长率为7.6％。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
		<item>
		<title>2017-2022年全球生物和医学影像试剂市场研究报告</title>
		<link>https://www.yuanzhezixun.com/2017-2022nianquanqiushengwuheyixueyingxiangshijishichangyanjiubaogao/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Mon, 15 Oct 2018 05:01:07 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Bayer AG (Germany)]]></category>
		<category><![CDATA[Bracco S.p.A (Italy)]]></category>
		<category><![CDATA[Bracco S.p.A（意大利]]></category>
		<category><![CDATA[GE Healthcare (The U.K)]]></category>
		<category><![CDATA[Guerbet (France)]]></category>
		<category><![CDATA[影像试剂]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=15821</guid>

					<description><![CDATA[全球生物和医学影像试剂市场预计将以8.0％（2017-2022）的复合年增长率增长，到2022年达到112.2亿美元的全球收入。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
